Interferon enhances tryptophan metabolism by inducing pulmonary indoleamine 2,3-dioxygenase: its possible occurrence in cancer patients.
Open accessThe DOI matches its Crossref record.
Abstract
Human lungs bearing cancer (n = 27) exhibited up to an approximately 20-fold [on average approximately 5-fold (P less than 0.005)] increase in the enzyme activity that degrades tryptophan to form formylkynurenine, in comparison with lungs with benign lesions (blebs) (n = 7) taken as controls. On the basis of molecular and kinetic properties, this activity was ascribed to indoleamine 2,3-dioxygenase (IDO) [indoleamine:oxygen 2,3-oxidoreductase (decyclizing)]. In vitro studies with human lung slices revealed that human interferon gamma (IFN-gamma) induced the de novo synthesis of IDO dose dependently (10-10(4) units/ml), and at maximum the activity reached nearly 100 times that in the control lungs described above. Human IFN-alpha also served as an inducer, but it was two to three orders of magnitude less potent than IFN-gamma relative to the antiviral titers, suggesting that IFN-gamma is the main mediator of the IDO induction. IDO thus induced in slices avidly metabolized tryptophan in situ: Upon a 24-hr incubation of lung slices pretreated with varied doses of IFN-gamma (10-10(3) units/ml), up to 96% of the tryptophan in the slices was depleted and up to 70% of the tryptophan in the medium was converted, mainly to formylkynurenine, kynurenine, or both. The foregoing results suggest that an IFN-mediated induction of IDO also takes place in vivo in human lungs as a response to cancer, leading to metabolic consequences such as depletion of tryptophan and accumulation of (formyl)kynurenine, which may provide a unique host defense mechanism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Kynurenine Pathway Metabolites in Humans: Disease and Healthy States
Chen, Y., & Guillemin, G. J. (2009) · International Journal of Tryptophan Research · doi:10.4137/ijtr.s2097 · Cited by 628
The Interferons: Mechanisms of Action and Clinical Applications
Baron, S. (1991) · JAMA · doi:10.1001/jama.1991.03470100067035 · Cited by 392
Kynurenine pathway in major depression: Evidence of impaired neuroprotection
Myint, A.-M., Kim, Y. K., Verkerk, R., Scharpé, S., Steinbusch, H., & Leonard, B. (2007) · Journal of Affective Disorders · doi:10.1016/j.jad.2006.07.013 · Cited by 527
Takikawa, O., Kuroiwa, T., Yamazaki, F., & Kido, R. (1988) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)77982-4 · Cited by 472
Simultaneous Measurement of Serum Tryptophan and Kynurenine by HPLC,
Widner, B., Werner, E. R., Schennach, H., Wachter, H., & Fuchs, D. (1997) · Clinical Chemistry · doi:10.1093/clinchem/43.12.2424 · Cited by 411
Indoleamine 2,3‐dioxygenase in T‐cell tolerance and tumoral immune escape
Katz, J. B., Muller, A. J., & Prendergast, G. C. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00610.x · Cited by 398
Lovelace, M. D., Varney, B., Sundaram, G., Lennon, M. J., Lim, C. K., Jacobs, K., Guillemin, G. J., & Brew, B. J. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.03.024 · Cited by 393
The therapeutic potential of targeting tryptophan catabolism in cancer
Opitz, C. A., Somarribas Patterson, L. F., Mohapatra, S. R., Dewi, D. L., Sadik, A., Platten, M., & Trump, S. (2020) · British Journal of Cancer · doi:10.1038/s41416-019-0664-6 · Cited by 300
Enzymology of NAD+ homeostasis in man
Magni, G., Amici, A., Emanuelli, M., Orsomando, G., Raffaelli, N., & Ruggieri, S. (2004) · Cellular and Molecular Life Sciences (CMLS) · doi:10.1007/s00018-003-3161-1 · Cited by 288
Network beyond IDO in psychiatric disorders: Revisiting neurodegeneration hypothesis
Myint, A.-M., & Kim, Y.-K. (2014) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.08.008 · Cited by 230
Neuropsychiatric disorders related to interferon and interleukins treatment
Myint, A. M., Schwarz, M. J., Steinbusch, H. W. M., & Leonard, B. E. (2009) · Metabolic Brain Disease · doi:10.1007/s11011-008-9114-5 · Cited by 116
Does escitalopram reduce neurotoxicity in major depression?
Halaris, A., Myint, A.-M., Savant, V., Meresh, E., Lim, E., Guillemin, G., Hoppensteadt, D., Fareed, J., & Sinacore, J. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2015.04.026 · Cited by 86
Tryptophan Metabolism and Immunogenetics in Major Depression: A Role for Interferon-γ Gene
Myint, A. M., Bondy, B., Baghai, T. C., Eser, D., Nothdurfter, C., Schüle, C., Zill, P., Müller, N., Rupprecht, R., & Schwarz, M. J. (2013) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2013.04.003 · Cited by 74
“, 1980) and by high cortisol (Salter and Pogson, 1985) whereas IDO activity is transcriptionally induced by the pro-inflammatory cytokines such as interferon-c (Carlin et al., 1987, 1989; Hu et al., 1995; Taylor and Feng, 1991; Yasui et al., 1986) and inhibited by anti-inflammatory cytokine, interleukin-4 (IL4) (Musso…”
BackgroundClaes, S., Myint, A.-M., Domschke, K., Del-Favero, J., Entrich, K., Engelborghs, S., De Deyn, P., Mueller, N., Baune, B., & Rothermundt, M. (2011) · Psychiatry Research · doi:10.1016/j.psychres.2011.03.012 · Cited by 65
Metabolites Associated With Circulating Interleukin-6 in Older Adults
Lustgarten, M. S., & Fielding, R. A. (2016) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glw039 · Cited by 44
Metadata
- Authors
- Yasui, H., Takai, K., Yoshida, R., & Hayaishi, O.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1986-09
- Volume
- 83
- Issue
- 17
- Pages
- 6622-6626
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2014837971
- Cited by
- 190
- References
- 0
- FWCI
- 2.00
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.